Analysis reveals MEQ cytokine enhances immune modulation in cancer and autoimmune diseases, suggesting potential therapeutic applications.
Amino Acid Sequence: The MEQ Cytokine is engineered to modulate immune responses, particularly in conditions such as cancer and autoimmune diseases. The sequence includes specific regions that enhance receptor binding and biological activity, tailored to minimize immunogenicity. Modifications: The cytokine may undergo PEGylation to extend its half-life and improve solubility. Additionally, glycosylation sites are strategically placed to enhance stability and reduce the potential for immune system recognition.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: